OR WAIT null SECS
© 2021 MJH Life Sciences and Modern Retina. All rights reserved.
© 2021 MJH Life Sciences™ and Modern Retina. All rights reserved.
June 24, 2021
In a study, a single intravitreal injection of ADVM-022 had a 99% reduction in the mean annualized frequency of anti-VEGF injections.
June 23, 2021
Investigators corroborate the hypothesis that retinal ganglion cells with dendrites stratified in the off sublaminae could be damaged.
June 18, 2021
According to investigators, the new technology is designed to detect telltale signs of major blinding diseases in retinal blood and tissue that typically go unseen until it is too late.
June 17, 2021
Amid pandemic, physicians and patients have embraced remote technology.
June 15, 2021
An updated PDS procedure reduces complications.
June 11, 2021
Standardization of Uveitis Nomenclature (SUN) Working Group utilized machine learning to create new uveitis classification criteria, inciting hope for implementation in clinical and research settings.
June 07, 2021
The not-for-profit vision and healthcare organization breaks ground on premier Technology Center for assistive technology for people with vision loss.
June 03, 2021
PDUFA action date of October 30, 2021, is assigned for investigational therapy with a proposed indication of treatment of macular edema associated with uveitis.
June 01, 2021
Retinal imaging tests are providing material to train and test decision support systems.
May 31, 2021
The company is hoping to commercialize the first FDA-approved ophthalmic formulation of bevacizumab-vikg for retinal disease. It expects to receive BLA approval from the FDA by mid-2022.